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ABSTRACT
Background 
UBE4B is an E3/E4 ubiquitin ligase whose gene is located in chromosome 
1p36.22. We analyzed the associations of UBE4B gene and protein expression with 
neuroblastoma patient outcomes and with tumor prognostic features and histology.
Methods 
We evaluated the association of UBE4B gene expression with neuroblastoma 
patient outcomes using the R2 Platform. We screened neuroblastoma tumor samples 
for UBE4B protein expression using immunohistochemistry. FISH for UBE4B and 1p36 
deletion was performed on tumor samples. We then evaluated UBE4B expression 
for associations with prognostic factors and with levels of phosphorylated ERK in 
neuroblastoma tumors and cell lines. 
Results
Low UBE4B gene expression is associated with poor outcomes in patients with 
neuroblastoma and with worse outcomes in all patient subgroups. UBE4B protein 
expression was associated with neuroblastoma tumor differentiation, and decreased 
UBE4B protein levels were associated with high-risk features. UBE4B protein levels 
were also associated with levels of phosphorylated ERK.
Conclusions 
We have demonstrated associations between UBE4B gene expression and 
neuroblastoma patient outcomes and prognostic features. Reduced UBE4B protein 
expression in neuroblastoma tumors was associated with high-risk features, a lack of 
differentiation, and with ERK activation. These results suggest UBE4B may contribute 
to the poor prognosis of neuroblastoma tumors with 1p36 deletions and that UBE4B 
expression may mediate neuroblastoma differentiation.
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INTRODUCTION
 Cases of high-risk neuroblastoma are associated 
with frequent relapses and tumors that are resistant to 
chemotherapy treatment, and children with refractory or 
recurrent neuroblastoma have poor responses to salvage 
therapy and very poor survival rates [1, 2]. A better 
understanding of the mechanisms of neuroblastoma 
tumorigenesis will likely provide improved treatment 
options for these children. 
Deletions in chromosome 1p36 have been detected 
in approximately one-third of neuroblastoma tumors and 
are associated with high-risk tumor features and a poor 
prognosis [3-5]. UBE4B is an E3/E4 ubiquitin ligase 
whose gene is located at chromosome 1p36.22 [6, 7], and 
UBE4B gene expression has been previously shown to 
be reduced in a cohort of high-stage tumors compared to 
low-stage tumors [8, 9]. We have identified an association 
between UBE4B gene expression and neuroblastoma 
patient outcomes [10], suggesting a potential role for 
UBE4B as a tumor suppressor gene. The functional 
role of UBE4B in neuroblastoma pathogenesis and its 
association with other prognostic factors, however, are 
poorly understood.
 We hypothesized that UBE4B gene and protein 
expression would be associated with neuroblastoma 
patient outcomes and other prognostic features and with 
neuroblastoma tumorigenesis. To explore the roles of 
UBE4B expression and function in the pathogenesis of 
neuroblastoma, we evaluated the association of UBE4B 
gene expression with neuroblastoma patient outcomes and 
prognostic features, and we investigated the expression 
of UBE4B protein in neuroblastoma tumor samples 
and its association with known prognostic features and 
downstream intracellular signaling pathways.
RESULTS
Association of UBE4B Gene Expression with 
Neuroblastoma Patient Outcomes
We evaluated the association of UBE4B gene 
expression with neuroblastoma patient outcomes, using 
results from microarray analyses of neuroblastoma 
tumors obtained from the R2 Genomics Analysis and 
Visualization Platform. Low expression of UBE4B 
was significantly associated with reduced event-free, 
relapse-free, and overall survival rates in two large 
patient cohorts (Figure 1A). Furthermore, UBE4B gene 
expression was significantly lower among patients who 
experienced disease relapse, compared to those who did 
not have disease relapse (Figure 1B), and the percentage 
Figure 1: Neuroblastoma Patient Outcomes Based on UBE4B Expression. A. Using the neuroblastoma Versteeg (top) and 
SEQC (bottom) patient data-sets in the R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl), patients were divided into 
high (blue) and low (red) UBE4B gene expression groups by median-centered Log2 ratios and survival curves were generated. Relapse-
free survival (top left), event-free survival (bottom left) and overall survival (right) curves are shown with patient numbers in parentheses. 
B. Relative UBE4B expression levels were plotted in patients with and without relapse from the Versteeg (top) and SEQC (bottom) patient 
data-sets, with patient numbers shown in parentheses. C. Numbers of patients with high or low UBE4B expression among patients either 
alive or dead at the time of data censoring for the Versteeg (top) and SEQC (bottom) data-sets.
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of deceased patients with low UBE4B expression in two 
separate datasets was 65.2% and 86.9%, respectively, 
compared to 27.7% and 11.9% among survivors (p 
= 0.0023 and p < 0.0001; Figure 1C). These results 
support the association of UBE4B gene expression with 
neuroblastoma patient outcomes, including an association 
between UBE4B gene expression and the risk of relapse 
and death.
Association of UBE4B gene expression with 
neuroblastoma patient prognostic features
To evaluate the potential association of UBE4B 
gene expression with known clinical and biological 
factors associated with neuroblastoma patient outcomes, 
we analyzed results from microarray analyses of 
neuroblastoma tumors. In neuroblastoma patient cohorts 
separated by treatment risk group, low UBE4B expression 
was associated with lower event-free and overall survival 
rates in patients with both low and intermediate risk 
neuroblastoma and in those with high-risk neuroblastoma 
(Figure 2A). UBE4B expression was also significantly 
lower in the cohort of patients with high-risk disease, 
compared to those with low and intermediate risk disease 
(p = 2.4e-43; Figure 2B). 
In neuroblastoma patient cohorts separated by 
tumor stage, low UBE4B gene expression was again 
associated with lower relapse-free, event-free, and overall 
survival rates in patients with both low stage and high 
stage disease (Figure 2C, Supplemental Figure 1) and 
with stage 4 disease separately (Supplemental Figure 1). 
Furthermore, UBE4B gene expression was significantly 
lower in patients with stage 4 disease compared to other 
stages (Figure 2D). In patient cohorts separated by patient 
age, low UBE4B gene expression was also associated with 
lower relapse-free, event-free, and overall survival rates 
in patients diagnosed at both less than and greater than 
18 months of age (Figure 2E, Supplemental Figure 2A), 
and UBE4B gene expression was inversely correlated with 
patient age at diagnosis (Significance of correlation: r = 
-0.327, p = 1.3e-13), with 215 out of 305 (70.5%) patients 
diagnosed at ≤18 months of age having high levels of 
UBE4B expression, compared to 65 out of 181 patients 
(35.9%) diagnosed at >18 months of age (p < 0.0001; 
Figure 2F, 2G). UBE4B expression was also significantly 
lower in a separate cohort of patients diagnosed at greater 
than 18 months of age, compared to those diagnosed at a 
younger age (Supplemental Figure 2B).
We have previously identified a potential association 
between low UBE4B gene expression and MYCN gene 
amplification [10]. To confirm the association between 
UBE4B expression and patient outcomes in patients 
with MYCN-amplified and non-amplified tumors, 
neuroblastoma patient cohorts were separated by the 
presence or absence of MYCN amplification. Patients with 
low UBE4B gene expression had lower rates of event-free 
and overall survival in cohorts with both MYCN amplified 
Figure 2: Neuroblastoma Patient Outcomes Based on UBE4B Expression and Known Neuroblastoma Prognostic 
Factors. A. Using the neuroblastoma SEQC patient data-set in the R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl), 
patients were divided into high (blue) and low (red) UBE4B gene expression groups by median-centered Log2 ratios and survival curves 
were generated for low and intermediate risk patients (left) and high risk patients (right). Event-free survival (top) and overall survival 
(bottom) curves are shown, with patient numbers in parentheses. B. Relative UBE4B expression levels were plotted in patients with non-
high risk (Non-HR) and high-risk (HR) disease.
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Figure 2: Neuroblastoma Patient Outcomes Based on UBE4B Expression and Known Neuroblastoma Prognostic 
Factors. A. Using the neuroblastoma SEQC patient data-set in the R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl), 
patients were divided into high (blue) and low (red) UBE4B gene expression groups by median-centered Log2 ratios and survival curves 
were generated for low and intermediate risk patients (left) and high risk patients (right). Event-free survival (top) and overall survival 
(bottom) curves are shown, with patient numbers in parentheses. B. Relative UBE4B expression levels were plotted in patients with non-
high risk (Non-HR) and high-risk (HR) disease. C. Using the neuroblastoma Versteeg (top) and SEQC (bottom) patient data-sets, survival 
curves were generated for patients with stage 1, 2, and 4S tumors (left) and with stage 3 and 4 tumors (right). Relapse-free survival (top) 
and event-free survival (bottom) curves are shown, with patient numbers in parentheses. D. Relative UBE4B expression levels from the 
Versteeg (top) and SEQC (bottom) patient data-sets were plotted in patients with stage 1, 2, 3, 4, and 4S disease, respectively, with patient 
numbers shown in parentheses. E. Using the neuroblastoma SEQC patient data-set, survival curves were generated for patients <18 months 
of age at diagnosis (left) and patients >18 months of age at diagnosis (right). Event-free survival (top) and overall survival (bottom) curves 
are shown, with patient numbers in parentheses. (F.,G.) Relative UBE4B expression levels were plotted compared to the age of patients at 
diagnosis for patients ≤18 months of age at diagnosis (F.) and for patients >18 months of age at diagnosis (G.).
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and non-amplified tumors (Figure 3, Supplemental Figure 
3A), with the most significant effects observed in the 
MYCN non-amplified cohort. Furthermore, UBE4B gene 
expression was also significantly lower in patients with 
MYCN amplified tumors compared to non-amplified 
tumors (p = 2.7e-47; Figure 3, Supplemental Figure 3B). 
These results demonstrate the association of low UBE4B 
gene expression with poor outcomes in all neuroblastoma 
patient subsets separated by clinically relevant prognostic 
factors.
Association of UBE4B gene expression with 
chromosome 1p36 deletion
The UBE4B gene is located within the chromosome 
1p36 region frequently deleted in neuroblastoma tumors, 
and therefore UBE4B represents a candidate tumor 
suppressor gene within this region. In order to determine 
whether UBE4B gene expression was correlated with 
chromosome 1p36 deletion, we analyzed results from 
datasets in the R2 Genomics Analysis and Visualization 
Platform with information about tumor 1p36 status. 
In two separate datasets, UBE4B gene expression was 
significantly lower in the tumors from patients with 
chromosome 1p36 deletion, compared to those with wild-
type chromosome 1p36, while the expression of three 
other genes located in the adjacent 1p36 region (TP73, 
HES2, and AJAP1) was unchanged (Figure 4), suggesting 
additional mechanisms of regulation of UBE4B gene 
expression are involved in neuroblastoma tumors. 
To determine whether the UBE4B gene was lost in 
all cases of chromosome 1p36 deletion, institutional tumor 
samples were analyzed by FISH for both 1p36 status 
and the UBE4B gene. Out of 34 tumor samples, 7 were 
found to have chromosome 1p36 loss, and all 7 also had 
loss of the UBE4B gene. Neither 1p36 nor UBE4B loss 
was identified in any of the remaining 27 tumor samples 
(Supplemental Figure 4), suggesting that loss of UBE4B 
likely occurs in the majority of cases of chromosome 1p36 
deletion.
UBE4B protein expression is associated with 
neuroblastoma tumor cell differentiation
To determine whether UBE4B protein expression 
was also associated with neuroblastoma patient outcomes 
and prognostic features, we analyzed neuroblastoma tumor 
samples for UBE4B expression by immunohistochemistry. 
In institutional tumor samples, reduction of 
UBE4B protein expression was only seen in poorly 
Figure 3: Neuroblastoma Patient Outcomes Based on UBE4B Expression and MYCN Amplification. A. Using the 
neuroblastoma SEQC patient data-set in the R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl), patients were divided 
into high (blue) and low (red) UBE4B gene expression groups by median-centered Log2 ratios and survival curves were generated for 
patients with non-MYCN amplified tumors (left) and with MYCN amplified tumors (right). Event-free survival (top) and overall survival 
(bottom) curves are shown, with patient numbers in parentheses. B. Relative UBE4B expression levels were plotted in patients with MYCN 
non-amplified and amplified tumors. 
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differentiated or undifferentiated neuroblastoma tumors 
or the poorly differentiated component of intermixed 
ganglioneuroblastomas, and UBE4B protein expression 
was significantly associated with neuroblastoma tumor 
differentiation in the cohort of samples (p < 0.0001; Figure 
5). 
To further analyze the association of UBE4B protein 
with neuroblastoma tumor differentiation, neuroblastoma 
tissue microarrays (TMAs) obtained from the Children’s 
Oncology Group (COG) (Supplemental Figure 5) were 
analyzed by immunohistochemistry for UBE4B protein 
expression and tumor differentiation. In TMA samples, 26 
of 43 differentiated tumor samples (61%) demonstrated 
increased UBE4B protein expression, compared to 24 out 
of 126 (19%) undifferentiated tumor samples (p < 0.0001; 
Figure 6A-6C). 
In order to evaluate whether UBE4B protein 
expression was correlated with any other known 
neuroblastoma prognostic factors, UBE4B staining 
intensity was compared in patient cohorts divided by 
tumor stage, treatment risk group, MYCN amplification, 
Shimada histology, and patient age at diagnosis. 37 out of 
44 low stage neuroblastoma tumors (84%) demonstrated 
UBE4B protein expression, including 9 out of 11 patients 
with stage 4S neuroblastoma (82%). By comparison, only 
11 of 20 (55%) untreated stage 4 tumors had UBE4B 
protein expression, with 9 out of 20 (45%) having absent 
UBE4B expression (p = 0.0024; Figure 6D). In samples 
obtained from patients with stage 4 disease obtained after 
chemotherapy treatment, 5 of 6 patients demonstrated 
increased UBE4B expression (83%; p = 0.0019), 
suggesting that an increase in UBE4B expression occurs in 
response to chemotherapy treatment in patients with stage 
4 neuroblastoma.
Further analysis also demonstrated that low UBE4B 
protein expression was significantly associated with high 
risk disease and unfavorable Shimada histology. Increased 
UBE4B protein expression was also seen in tumors 
with non-amplified MYCN and in tumors from patients 
diagnosed at over 18 months of age, but these trends did 
not reach statistical significance (Figure 6E). In samples 
with available information about patient outcomes, 
we observed that low UBE4B protein expression was 
associated with a non-significant trend towards decreased 
survival (Supplemental Figure 6), further suggesting 
that the association of UBE4B gene expression with 
neuroblastoma patient outcomes is mediated by UBE4B 
protein expression and function.
Figure 4: UBE4B Expression Compared to Chromosome 1p36 Status. Using the R2 Genomics Analysis and Visualization 
Platform, UBE4B gene expression in the Lastowska (A.) and Maris (B.) datasets was compared in patients with wild-type chromosome 1p 
(left) or with 1p36 deletion (right), with patient numbers shown in parentheses. Expression of TP73 (C.), HES2 (D.), and AJAP1 (E.) in 
patients with wild-type chromosome 1p (left) or with 1p36 deletion (right) was compared in the Lastowska dataset.
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UBE4B expression in neuroblastoma tumor cells 
is increased after retinoic acid treatment and is 
associated with RAS/MAPK pathway activity
To evaluate changes in UBE4B gene expression 
during neuroblastoma tumor cell differentiation, we 
performed RNA-sequencing on neuroblastoma tumor cells 
before and after 13-cis-retinoic acid (CRA) treatment. 
In SK-N-BE(2), SK-N-SH, and IMR-32 neuroblastoma 
tumor cell lines tested after 48 hours of retinoic acid 
exposure, UBE4B gene expression increased by an 
average of 23.1% (+/- 19.6%)(Supplemental Figure 7).
ERK activation has been shown to correlate 
with nerve growth factor-induced neuroblastoma cell 
differentiation [11], suggesting a role for the RAS/
MAPK pathway in neuroblastoma differentiation. In 
order to determine whether UBE4B expression was also 
associated with RAS/MAPK pathway signaling activity 
in neuroblastoma tumor cells, we determined levels of 
UBE4B and total and phosphorylated MEK and ERK 
expression in established neuroblastoma cell lines and 
patient tumor samples. Neuroblastoma cell lines and 
tumors demonstrated varying levels of phosphorylated 
MEK and ERK. In both cell lines and patient tumor 
samples, decreased UBE4B expression was associated 
with the highest levels of phosphorylated ERK, while 
cell lines with increased UBE4B had lower levels of 
phosphorylated ERK (Figure 7), suggesting an inverse 
association between UBE4B levels and RAS/MAPK 
pathway activity and providing a mechanistic link between 
UBE4B protein expression and neuroblastoma tumor 
differentiation.
DISCUSSION
Children with high-risk neuroblastoma have 
extremely poor outcomes, and additional understanding 
of the pathways involved in neuroblastoma pathogenesis 
will assist in the development of improved therapies. 
The UBE4B gene is located in chromosome 1p36.22, a 
commonly deleted chromosomal region in neuroblastoma 
tumors, and our results demonstrate an association of 
UBE4B gene and protein expression with neuroblastoma 
patient outcomes and prognostic features and of 
UBE4B protein levels with neuroblastoma tumor cell 
differentiation, suggesting a role for UBE4B as a novel 
tumor suppressor gene.
We previously identified an interaction between 
UBE4B and the endosomal membrane protein hepatocyte 
growth factor-regulated tyrosine kinase substrate (Hrs), 
and we have demonstrated that the UBE4B-Hrs interaction 
is critical for appropriate growth factor receptor GFR 
trafficking and degradation [7, 10, 12], suggesting a 
previously undiscovered link between GFR trafficking 
and neuroblastoma pathogenesis. Recent studies have 
identified a role for TrkA ubiquitination by the ubiquitin 
ligase Cbl-b in neuroblastoma differentiation [11], 
further suggesting a link between receptor trafficking and 
neuroblastoma pathogenesis.
We have identified an association between UBE4B 
protein expression and poor prognostic features for 
children with neuroblastoma, although we were unable 
to demonstrate a significant association between UBE4B 
protein expression and patient outcomes. These analyses 
were limited by the small number of patients with 
outcomes data available and the limited number of events 
Figure 5: Reduced UBE4B Expression Is Associated with Poorly Differentiated Tumors. A.-D. Formalin-fixed tumor samples 
were obtained from the Texas Children’s Hospital tissue bank and sections were stained for the UBE4B protein by immunohistochemistry; 
A. Undifferentiated neuroblastoma (nbl) adjacent to normal adrenal cortex (AC); B. Poorly differentiated neuroblastoma nodule (PD, 
bottom right corner) adjacent to a differentiating neuroblastoma nodule (DN, upper left corner); C. Poorly differentiated neuroblastoma 
containing scattered ganglion-like cells (arrows); D. differentiating neuroblastoma tumor. E. UBE4B staining and differentiation status 
information from institutional tumor samples was compiled and compared.
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among those patients. Further analyses using larger patient 
cohorts will be needed to confirm the potential association 
between protein expression and patient survival. Further 
studies are also needed to confirm whether UBE4B protein 
function is also linked to patient prognosis and whether 
UBE4B plays a functional role in neuroblastoma tumor 
differentiation.
Although we have demonstrated associations 
between UBE4B gene and protein expression and a 
number of critical neuroblastoma prognostic variables, 
studies are ongoing to determine whether UBE4B 
expression is independently associated with neuroblastoma 
patient outcomes. We have shown that neuroblastoma 
tumors with 1p36 deletion have lower UBE4B expression 
levels, suggesting that decreased UBE4B gene expression 
is a potential contributor to the poor prognosis of 
neuroblastoma patients with 1p36 deletions. However, a 
large number of genes located within the 1p36 region have 
been proposed as tumor suppressors in neuroblastoma and 
other tumors, including CHD5 [13], CAMTA1 [14, 15], 
miRNA-34a [16, 17], CASZ1 [18], KIF1B [19, 20], and 
the HES gene family [21]. Low expression levels of many 
of these genes have been correlated with poor patient 
outcomes, suggesting that 1p36 deletion may impact 
prognosis via effects on multiple independent pathways. 
However, the lack of effect of 1p36 deletion on the 
expression of all genes in this region suggests that other 
mechanisms of gene regulation are involved. We were 
unable to find any tumors where UBE4B was lost in the 
absence of 1p36 deletion. However, the number of patient 
Figure 6: UBE4B Expression in Neuroblastoma Tumor Tissue Arrays. Neuroblastoma tumor tissue microarrays (TMAs) were 
obtained from COG and were stained for UBE4B. Representative samples with positive staining (A.) and negative staining (B.) are shown. 
Scale bars are equal to 1 mm. (C.) UBE4B staining score was determined in blinded fashion and compared to tumor differentiation in each 
sample. UBE4B staining score was also compared to tumor stage (D.) and other prognostic features (E.).
Genes & Cancer21www.impactjournals.com/Genes&Cancer
samples screened was small and does not preclude cases 
of 1p36 deletion without loss of UBE4B, or of UBE4B 
loss in the absence of 1p36 deletion. Furthermore, the 
association of low UBE4B expression with worse patient 
outcomes in all patient subsets suggests that alternate 
mechanisms regulating UBE4B gene expression other 
than 1p36 deletion are likely involved in neuroblastoma 
tumors. Further studies are underway to identify whether 
other genetic or epigenetic events are responsible for 
regulation of UBE4B gene expression.
The significant association of low UBE4B 
expression with lower survival rates in cohorts of low 
stage and younger patients suggests UBE4B may be 
a novel predictor of relapse in children with low and 
intermediate risk neuroblastoma. Prior studies have 
identified chromosome 1p loss of heterozygosity (LOH) 
as a prognostic indicator for disease recurrence in 
children with localized neuroblastoma [22], and have also 
determined that alternations in both chromosome 1p and 
11q are poor prognostic factors in patients with low stage 
neuroblastoma [23]. Prior studies have also identified 
gene expression profiles able to differentiate infant stage 
4 from stage 4S neuroblastoma [24]. For these infants with 
metastatic disease, UBE4B protein expression may serve 
as a novel molecular marker to distinguish stage 4 from 4S 
disease, and UBE4B expression and function may underlie 
the dramatic clinical and biologic differences between 
these two subtypes of neuroblastoma.
The role of RAS/MAPK pathway signaling 
in neuroblastoma tumor cells is poorly understood. 
Activating mutations in the genes of members of the RAS/
MAPK pathway have been identified in a small subset 
of neuroblastoma tumors [25] at diagnosis and more 
frequently at relapse [26]. Furthermore, expression of the 
gene for the Ras GTPase-activating protein (RasGAP) 
NF1 is also associated with neuroblastoma patient 
outcomes [27, 28], suggesting a more significant role for 
the RAS/MAPK pathway in neuroblastoma pathogenesis 
and disease relapse.
The mechanisms underlying neuroblastoma tumor 
cell differentiation are poorly understood. A number of 
proteins have been shown to be required for or involved 
in the effects of CRA on neuroblastoma tumor cells, 
including RET (29,30), REST (31), and ZNF423 (32). The 
expression of the Chromodomain-helicase DNA binding 
protein 5 (CHD5) gene was recently shown to be elevated 
Figure 7: UBE4B, MEK, and ERK Expression in Neuroblastoma Tumor Cell Lines and Tissue Samples. (A.)
Neuroblastoma patient samples were lysed and Western blots for UBE4B and phosphorylated ERK were performed. Vinculin and actin were 
used as loading controls. (B.) A panel of neuroblastoma cell lines were lysed and Western blots for UBE4B and for total and phosphorylated 
MEK and ERK were performed. Vinculin and actin was used as loading controls. Densitometry analysis was performed to quantify relative 
phospho-ERK and UBE4B protein levels in neuroblastoma tumor samples (C.) and cell lines (D.) Spearman’s correlation analysis was 
performed with UBE4B and pERK protein levels as shown. R = -0.7381 and p = 0.03655 for tumor samples (C.) and R = -0.78333 and p 
= 0.01252 for cell lines (D.).
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after 7 days of CRA treatment in SH-SY5Y, NGP, and SK-
N-DZ neuroblastoma cells (33), although the increased 
expression was seen after the induction of morphologic 
neuroblastoma differentiation. The relative role of UBE4B 
and other proteins in the induction of differentiation 
remain unclear, and further studies are underway to further 
delineate the mechanisms underlying this process.
We have confirmed an association between 
UBE4B expression and neuroblastoma patient outcomes 
and prognostic features and demonstrated that reduced 
UBE4B expression in neuroblastoma tumors was 
associated with a lack of differentiation. This link 
between a known cytogenetic risk factor, GFR trafficking, 
and neuroblastoma tumor histology suggests UBE4B-
mediated GFR trafficking may contribute to the poor 
prognosis of neuroblastoma tumors with 1p36 deletions. 
UBE4B therefore represents a novel molecular marker 
of neuroblastoma tumor differentiation and intratumoral 
heterogeneity and also represents a potential target for 
novel drug development.
MATERIALS AND METHODS
Neuroblastoma cell lines and culture conditions
The neuroblastoma cell lines used in this study have 
been previously described [34-41] and were generously 
provided by Shahab Asgharzadeh (Children’s Hospital Los 
Angeles, Los Angeles, CA), Susan Cohn (The University 
of Chicago Children’s Hospital, Chicago, IL), Jill Lahti 
(St. Jude Children’s Research Hospital, Memphis, 
TN), John Maris (Children’s Hospital of Philadelphia, 
Philadelphia, PA), William Weiss (The University of 
California, San Francisco, San Francisco, CA) or were 
purchased from the American Type Culture Collection 
(ATCC; Rockville, MD). Cell lines were grown at 37° 
in 5% CO2 in appropriate media (Invitrogen, Carlsbad, 
CA) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) (Life Technologies, Grand Island, NY), 
L-glutamine, sodium pyruvate, and non-essential amino 
acids as previously described [42]. All cell lines were 
authenticated by DNA profiling prior to use. 
Neuroblastoma patient tumor samples and data
Representative formalin-fixed, paraffin embedded 
(FFPE) tumor tissue blocks were selected for the study 
following histological case review (RJG and DLT) 
and retrieved from the archives of the Texas Children’s 
Hospital Department of Pathology. Fresh frozen patient 
tumor samples were obtained from the Texas Children’s 
Hospital Research Tissue Support Services (RTSS). Fresh 
resected neuroblastoma tumor samples were collected 
from patients after informed consent was obtained 
via an Institutional Review Board-approved tissue 
banking protocol. Samples were placed in sterile human 
stem cell media and flash frozen in liquid nitrogen for 
storage by RTSS. Neuroblastoma patient tumor tissue 
microarrays (TMAs) were provided by the Children’s 
Oncology Group Neuroblastoma Biology Committee 
and the Biopathology Center in Columbus, OH [10]. We 
obtained microarray analysis results of neuroblastoma 
patient tumor samples from the R2 Genomics Analysis 
and Visualization Platform (http://r2.amc.nl) using the 
Versteeg, SEQC, Lastowska, and Maris databases, which 
included comprehensive information on the relevant 
clinical and prognostic factors selected for analysis. 
UBE4B probesets in each database with the highest 
average signals (Versteeg probeset 202317_s_at; SEQC 
probeset NM_006048; Lastowska probeset 202317_s_at; 
Maris probeset 41339_at) were selected for analysis. All 
experiments utilizing patient tissue samples and analyzing 
patient information were approved by the Baylor College 
of Medicine Institutional Review Board.
Immunohistochemistry
Formalin-fixed paraffin embedded (FFPE) tissue 
specimens from 35 archival neuroblastoma cases 
diagnosed at Texas Children’s Hospital were used for 
immunohistochemical (IHC) stains. After heat-induced 
antigen retrieval in Target Retrieval Solution following 
the manufacturer’s instructions (S1699; Dako, Carpinteria, 
CA), IHC staining was performed using the ImmPRESS 
HRP rabbit polyclonal detection kit (Vector Laboratories; 
Burlingame, CA) with a polyclonal antibody to UBE4B 
(ab97697; 1:400; Abcam, Cambridge, MA). Anaplastic 
medulloblastoma tissue samples were used as positive 
controls for UBE4B staining [43] in addition to internal 
control cells, such as adjacent adrenal cortical epithelial 
cells or ganglion cells. Slides were de-identified and 
randomly distributed to two diagnostic pathologists 
(RJG and DLT) for evaluation. Immunoreactivity was 
categorized as negative/reduced or positive. “Negative/
reduced” was defined as reduced or absent UBE4B 
staining intensity in at least 50% of the tumor cells 
compared to positive external and internal controls. 
“Positive” was defined as UBE4B staining intensity 
similar to or stronger than positive external and internal 
controls in at least 50% of the tumor cells. Neuroblastoma 
tumor differentiation was determined using standard 
criteria as previously described [44]. Photographs of 
stained tumor samples were taken using an Olympus DP71 
camera attached to a Nikon Eclipse E100 microscope at 
20x magnification.
For immunohistochemical staining of TMA tumor 
samples, TMA slides were deparaffinized and hydrated. 
Slides were boiled in Target Retrieval Solution (Dako) 
and blocked with 10% normal serum with 1% BSA in 
TBS. UBE4B primary antibody (ab97697, Abcam) was 
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diluted 1:400 in SignalStain Antibody Diluent (Cell 
Signaling, Danvers, MA), and TMAs were incubated with 
UBE4B antibodies for 30 minutes at room temperature. 
UBE4B signal was detected using SignalStain Boost 
Detection Reagent (Cell Signaling) and SignalStain DAB 
Chromogen Concentrate (Cell Signaling). Slides were then 
counterstained with CAT hematoxylin (Biocare Medical, 
Concord, CA) and bluing reagent (VWR, Radnor, PA). 
Finally, slides were dehydrated and coverslips were 
mounted with Cytoseal XYL (Thermo Fisher Scientific, 
Waltham, MA). Slides were visualized using an inverted 
microscope (Nikon Eclipse TE-300, Nikon, Tokyo, 
Japan) and images were acquired on an RS Photometrics 
CoolSNAP color digital camera (Roper Scientific, 
Photometrics, Tucson, AZ) using RS Photometrics Image 
Software Version 1.9.2 (Roper Scientific, Photometrics, 
Tucson, AZ).
Tissue microarrays stained as above with antibodies 
to UBE4B were scored for both intensity of expression 
(scored 0-3) and extent of staining (scored 0-3) to give a 
10 point multiplicative staining index of 0-9 as described 
previously [45] by a pathologist (MI) blind to patient 
identities, features, and outcomes.
Fluorescence in situ hybridization (FISH)
We used institutional FFPE tissue specimens 
described above for FISH analyses. To detect the UBE4B 
gene copy number in neuroblastoma tumor samples, two 
BAC clones targeting the UBE4B gene, CTD-2254N9 and 
CTD-2171J21 (Life Technologies), were developed using 
a nick-translation kit (Abbott Molecular, Abbott Park, 
IL). FISH analyses for the centromere of chromosome 1, 
chromosome 1q25, and for chromosome 1p36 deletion 
were performed using a commercially available probes 
(CEP1, Vysis 1p36/1q25 Probe Kit; Abbott Molecular). 
Western blots
To measure the levels of proteins in patient samples, 
samples were homogenized on ice, then incubated for 
30 minutes in radioimmunoprecipitation assay (RIPA) 
protein lysis buffer containing protease inhibitors (Sigma) 
and phosphatase inhibitors (Roche, San Francisco, CA) 
with homogenization every 10 minutes. Lysates were 
centrifuged and supernatants were collected. For protein 
levels in neuroblastoma cell lines, cells were plated in 
100-mm plates and allowed to adhere and proliferate for 
two days with media being replaced with fresh media 
after one day. Cells from plates at approximately 80% 
confluency were then harvested and lysed as above. 
Protein concentration in each sample lysate was 
measured using a protein assay dye reagent (Bio-Rad, 
Hercules, CA). 30-50 μg total denatured protein from each 
cell line or tumor sample lysate was separated by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to nitrocellulose (Invitrogen) 
or polyvinylidene fluoride (PVDF) membranes using 
standard techniques. Membranes were blocked in Odyssey 
blocking buffer (Li-Cor, Lincoln, NE) for two hours at 
room temperature and then incubated overnight with 
primary antibodies to total MEK (9126; 1:1000; Cell 
Signaling), phosphorylated MEK (9154; 1:1000; Cell 
Signaling), total ERK (4695; 1:1000; Cell Signaling), 
phosphorylated ERK (4370; 1:2000; Cell Signaling), 
UBE4B (ab97697; 1:1000; Abcam), Actin (A5316 or 
A5441; 1:5000; Sigma), or Vinculin (1:10000; ab1290002; 
Abcam). Bound primary antibodies were incubated for 
two hours at room temperature with IRDye800 conjugated 
affinity purified anti-rabbit or anti-mouse secondary 
antibodies (1:5000; Rockland, Gilbertsville, PA), and the 
signal was visualized using an Odyssey infrared imaging 
system (Li-Cor).
RNA-sequencing
SK-N-BE(2), SK-N-SH, and IMR-32 neuroblastoma 
tumor cells were seeded at 60-70% confluence and 
allowed to attach for 24 hours, with four plates per cell 
line. Cells in two plates for each cell line were treated 
with 5 µM 13-cis-retinoic acid for 48 hours, while 
other plates were left untreated. Cells were washed with 
PBS and lysed in the plates using Qiagen lysis buffer 
(Qiagen, Valencia, CA), and cell lysates from individual 
plates were homogenized separately using QIAshredder 
(Qiagen). Total cellular RNA was harvested from each 
lysate separately using the Qiagen mini RNeasy kit 
(Qiagen), following the manufacturer’s instructions. RNA 
sample quality was confirmed using a NanoDrop 2000 
spectrophotometer (Thermo Scientific, Wilmington, DE) 
and Agilent Bioanalyzer 2100 (Agilent Technologies, 
Santa Clara, CA). A double-stranded DNA library was 
created using the Illumina TruSeq RNA library preparation 
protocol. 250ng of total RNA, quantitated by picogreen, 
was used for each sample. cDNA was created using the 
fragmented 3’ poly (A) selected portion of total RNA and 
random primers. Libraries were created from the cDNA by 
first blunt ending the fragments, attaching an adenosine to 
the 3’ end and finally ligating unique adapters to the ends. 
The ligated products were then amplified using 15 cycles 
of PCR. The resulting libraries were quantitated using the 
NanoDrop spectrophotometer and fragment size assessed 
with the Agilent 2100 Bioanalyzer. A qPCR assay was 
performed on the libraries to determine the concentration 
of adapter ligated fragments using the Applied Biosystems 
ViiA 7 Quantitative PCR instrument and a KAPA Library 
Quant Kit. All samples were pooled equimolar and re-
quantitated by qPCR, and re-assessed on the Bioanalyzer. 
Using the pooled concentration from the qPCR assay, the 
library pool was loaded onto each of two high output mode 
lanes at a concentration of 15pM, for cluster generation on 
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the cBot and sequencing on the HiSeq 2500 (Illumina, San 
Diego, CA) at a read length of 100bp, using paired-end v3 
chemistry.
Statistical analysis
All microarray data generated from the R2 Genomics 
Analysis and Visualization Platform was analyzed 
using the R2 program for analysis and visualization of 
microarray data (http://r2.amc.nl). Kaplan-Meier analyses 
and comparisons of UBE4B expression between different 
patient subgroups were performed online and the resulting 
survival curves, box plots, and p values (obtained via the 
log-rank test) were downloaded as previously described 
[46]. Comparisons between UBE4B staining intensity and 
clinical or biologic variables were made using Chi-squared 
or Fisher-Exact tests, as appropriate.
Outcomes for patients for neuroblastoma TMA 
samples were obtained from COG. Patients were divided 
into high and low UBE4B protein expression groups 
according to their average multiplicative staining scores 
on TMA slides. The high-expression group contained 
12 patients and the low-expression group contained 7 
patients. Kaplan-Meier survival curves were plotted using 
the open-source statistical packages in R (http://www.r-
project.org). Survival curves were compared by UBE4B 
protein expression groups using the log-rank test to 
examine the association between UBE4B expression and 
patient survival outcomes in TMA samples. 
For RNA-sequencing analysis, 101-nucleotide 
reads were trimmed to 90 nucleotides by removing the 
low-quality nucleotides from the 5’ and 3’ ends of the 
reads. The resulting 90-nucleotide pair-ended reads 
were mapped to the human genome (UCSC hg19) using 
Tophat [47] with NCBI RefSeq genes as the reference. 
In order to reduce possible PCR biases, we removed the 
read duplicates using picard tools (http://broadinstitute.
github.io/picard/). HTseq (http://www-huber.embl.de/
users/anders/HTSeq) was used to determine the number 
of reads falling in the known genes. EdgeR [48] and 
DESeq2 [49] were used to analyze the gene-based read 
counts to detect differentially expressed genes between 
the groups of interest. The false discovery rate (FDR) of 
the differentially expressed genes was estimated using 
Benjamini and Hochberg method [50]. FDR < 0.05 was 
considered statistically significant. 
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